Tango Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Tango Therapeutics (NASDAQ: TNGX), a clinical-stage biotechnology company focused on precision cancer medicine, is set to participate in key investor conferences this February. The first event is the Guggenheim Healthcare Talks | 2023 Oncology Conference on February 9, 2023, at 1:00 PM ET in New York. The second is the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET, conducted virtually. Live webcasts will be available on the Company's website, with replays archived post-presentation. Tango is committed to advancing cancer treatment through innovative drug targets and leveraging synthetic lethality principles.

BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in February.

Guggenheim Healthcare Talks | 2023 Oncology Conference
Date: Thursday, February 9, 2023
Time: 1:00 PM ET
Location: New York, NY

SVB Securities Global Biopharma Conference
Date: Thursday, February 16, 2023
Time: 9:20 AM ET
Location: Virtual

A live webcast of the presentations will be available under the "Events & Presentations" tab on the “Investors” page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website following the presentation.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com.

Investor Contact:
Sam Martin/Andrew Vulis
Argot Partners
tango@argotpartners.com

Media Contact:
Joshua R. Mansbach
Argot Partners
tango@argotpartners.com

FAQ

What are the details of Tango Therapeutics' upcoming conferences in February 2023?

Tango Therapeutics will participate in the Guggenheim Healthcare Talks | 2023 Oncology Conference on February 9, 2023, at 1:00 PM ET, and the SVB Securities Global Biopharma Conference on February 16, 2023, at 9:20 AM ET.

Where can I watch the presentations from Tango Therapeutics' investor conferences?

The presentations will be available via live webcast on the 'Events & Presentations' tab of Tango Therapeutics' website, with replays archived after the events.

What is the focus of Tango Therapeutics as a biotechnology company?

Tango Therapeutics is dedicated to discovering novel drug targets and developing precision cancer medicines, focusing on synthetic lethality in cancer treatments.

What is the significance of the conferences for investors interested in TNGX?

The conferences provide investors an opportunity to gain insights into Tango Therapeutics’ strategies, research developments, and future directions in cancer treatment.